The company continues to report zero revenue while sustaining significant quarterly net losses, which peaked at $6.0 million in 2024Q3, reflecting a lack of operational leverage.
Telomir Pharmaceuticals, Inc. Common Stock (TELO) annual income statement — 5-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 |
|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - |
| Operating Expenses | 6.09M | 10.54M | 12.24M | 3.94M | 854.15K | 138.13K |
| OpEx % of Revenue | - | - | - | - | - | - |
| Selling, General & Admin | 3.12M | 8.1M | 9.64M | 600.19K | 20.94K | 11.64K |
| SG&A % of Revenue | - | - | - | - | - | - |
| Research & Development | 2.97M | 2.44M | 2.24M | 1.57M | 833.21K | 126.49K |
| R&D % of Revenue | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 370.5K | 1.77M | 0 | 0 |
| Operating Income | -6.09M | -10.54M | -12.24M | -3.94M | -854.15K | -138.13K |
| Operating Margin % | - | - | - | - | - | - |
| Operating Income Growth % | - | 13.91% | -210.55% | -361.52% | -518.36% | - |
| EBITDA | -5.87M | -10.41M | 0 | -11.43M | 0 | 0 |
| EBITDA Margin % | - | - | - | - | - | - |
| EBITDA Growth % | 63.62% | - | 100% | - | - | - |
| D&A (Non-Cash Add-back) | 0 | 0 | 12.24M | 0 | 854.15K | 138.13K |
| EBIT | -5.87M | -10.41M | -12.19M | -11.43M | -854.15K | -138.13K |
| Net Interest Income | 207.14K | 125.64K | 4.39M | -1.64M | 0 | 0 |
| Interest Income | 214.15K | 125.64K | 48K | 0 | 0 | 0 |
| Interest Expense | 7.01K | 0 | -4.34M | 1.64M | 0 | 0 |
| Other Income/Expense | 211.21K | 125.64K | -4.29M | -9.13M | 0 | 0 |
| Pretax Income | -5.88M | -10.41M | -16.53M | -13.07M | -854.15K | -138.13K |
| Pretax Margin % | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -5.88M | -10.41M | -16.53M | -13.07M | -854.15K | -138.13K |
| Net Margin % | - | - | - | - | - | - |
| Net Income Growth % | 63.59% | 37.01% | -26.48% | -1430.4% | -518.36% | - |
| Net Income (Continuing) | -5.88M | -10.41M | -16.53M | -13.07M | -854.15K | -138.13K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.17 | -0.33 | -0.56 | -0.44 | -0.03 | -0.00 |
| EPS Growth % | -179.75% | 41.07% | -27.27% | -1427.78% | - | - |
| EPS (Basic) | - | -0.33 | -0.56 | -0.44 | -0.03 | -0.00 |
| Diluted Shares Outstanding | 34.38M | 31.65M | 29.54M | 29.61M | 29.61M | 29.61M |
| Basic Shares Outstanding | 34.38M | 31.65M | 29.54M | 29.61M | 29.61M | 29.61M |
| Dividend Payout Ratio | - | - | - | - | - | - |
Quick answers to the most common questions about buying TELO stock.
For fiscal year 2025, Telomir Pharmaceuticals, Inc. Common Stock (TELO) reported total revenue of $0.0M.
Telomir Pharmaceuticals, Inc. Common Stock (TELO) reported a net loss of $10.4M for the fiscal year ending 2025.
Key Metrics
Top Statement Risk
Binary clinical trial failure
Metrics are mathematically derived from official filings.
Volatile R&D and G&A Spending
As reported in financial statements, TELO's operating expenses exhibit significant quarterly volatility, with R&D spending fluctuating between $42.8K and $1.3M, while SG&A costs peaked at $5.4M in 2024Q3, reflecting an inconsistent approach to resource allocation during this critical pre-clinical development phase for the company.
The erratic nature of SG&A expenses suggests a lack of disciplined cost control, which is particularly concerning for a pre-revenue entity with limited cash reserves. Investors should monitor whether these spikes represent one-time administrative burdens or a structural inability to manage overhead while pursuing IND enablement.
Dilutive Impact of Stock Compensation
Based on the company's historical income statements, TELO recognized significant stock-based compensation totaling $8.3M across 2024 and 2025, which obscures the underlying cash burn and suggests that management is relying heavily on equity-based incentives to preserve limited liquid assets during this pre-clinical stage.
The reliance on stock-based compensation effectively shifts the cost of talent acquisition onto existing shareholders, further diluting their interest in a company that has yet to generate revenue. This practice warrants further investigation into the alignment between executive compensation and the achievement of tangible clinical milestones.
Operating Leverage Remains Entirely Absent
According to recent SEC filings, TELO's operating losses remain substantial, with quarterly net losses reaching as high as $6.0M in 2024Q3, confirming that the company lacks any operational leverage as it continues to burn through capital without a corresponding increase in commercial or research output.
The absence of revenue means that every dollar spent on R&D and G&A flows directly to the bottom line as a loss, leaving no room for operational efficiency. Until the company achieves a clinical inflection point, the income statement will likely continue to reflect a pure cash-burn profile.
Sustainability of Current Cash Runway
As indicated by the provided financial data, the company's $7.2M cash position appears insufficient to support the high-cost requirements of human clinical trials, suggesting that TELO may face a liquidity crisis unless it secures additional non-dilutive funding or enters a partnership in the near term.
Short-sellers would likely focus on the widening gap between the company's ambitious longevity narrative and its precarious financial reality. The lack of a clear path to self-funding implies that the current valuation may be disconnected from the high probability of future equity dilution.